Ebola virus disease

ST Jacob, I Crozier, WA Fischer, A Hewlett… - Nature reviews Disease …, 2020 - nature.com
Ebola virus disease (EVD) is a severe and frequently lethal disease caused by Ebola virus
(EBOV). EVD outbreaks typically start from a single case of probable zoonotic transmission …

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

S Wang, B Liang, W Wang, L Li, N Feng… - Signal transduction and …, 2023 - nature.com
Human diseases, particularly infectious diseases and cancers, pose unprecedented
challenges to public health security and the global economy. The development and …

Current state of Ebola virus vaccines: A snapshot

C Woolsey, TW Geisbert - PLoS pathogens, 2021 - journals.plos.org
Four species of the genus Ebolavirus cause severe and often lethal disease in humans:
Sudan ebolavirus (SUDV), Bundibugyo ebolavirus (BDBV), Taï Forest ebolavirus (TAFV) …

The economic lives of young women in the time of Ebola: lessons from an empowerment program

O Bandiera, N Buehren, M Goldstein… - World Bank Policy …, 2019 - papers.ssrn.com
This paper evaluates an intervention to raise young women's economic empowerment in
Sierra Leone, where women frequently experience sexual violence and face multiple …

Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control

S Wang, W Li, Z Wang, W Yang, E Li, X Xia… - Signal transduction and …, 2024 - nature.com
To adequately prepare for potential hazards caused by emerging and reemerging infectious
diseases, the WHO has issued a list of high-priority pathogens that are likely to cause future …

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

A Fathi, C Dahlke, MM Addo - Human vaccines & …, 2019 - Taylor & Francis
The devastating Ebola virus (EBOV) outbreak in West Africa in 2013–2016 has flagged the
need for the timely development of vaccines for high-threat pathogens. To be better …

A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge

C Woolsey, RW Cross, KN Agans… - PLoS neglected …, 2022 - journals.plos.org
Background Marburg virus (MARV), an Ebola-like virus, remains an eminent threat to public
health as demonstrated by its high associated mortality rate (23–90%) and recent …

Immunovirotherapy based on recombinant vesicular stomatitis virus: where are we?

Y Zhang, BM Nagalo - Frontiers in immunology, 2022 - frontiersin.org
Vesicular stomatitis virus (VSV), a negative-strand RNA virus of the Vesiculovirus genus, has
demonstrated encouraging anti-neoplastic activity across multiple human cancer types. VSV …

Prevention of Ebola virus disease through vaccination: where we are in 2018

Y Lévy, C Lane, P Piot, AH Beavogui, M Kieh, B Leigh… - The Lancet, 2018 - thelancet.com
In 2016, Guinea, Liberia, and Sierra Leone succeeded in interrupting the longest epidemic
of Ebola virus disease in global history. 1 Control of the epidemic was primarily achieved by …

Immunogenicity, lot consistency, and extended safety of rVSVΔG-ZEBOV-GP vaccine: a phase 3 randomized, double-blind, placebo-controlled study in healthy adults

SA Halperin, R Das, MT Onorato, K Liu… - The Journal of …, 2019 - academic.oup.com
Background This double-blind study assessed immunogenicity, lot consistency, and safety
of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine …